Anonymous User
Login / Registration

a hepatologie

Gastroenterology and Hepatology

Gastroent Hepatol 2021; 75(1): 72–83. doi: 10.14735/amgh202172.

Proton pump inhibitors – do we know them well and are they really that safe? – part 3

Jan Bultas1

+ Affiliation

To read this article in full, please register for free on this website.

Benefits for subscribers

Benefits for logged users


6. Huijgen NA, de Ridder MAJ, Verhamme KM et al. Are proton-pump inhibitors harmful for the semen quality of men in couples who are planning pregnancy? Fertil Steril 2016; 106 (7): 1666–1672. doi: 10.1016/ j.fertnstert. 2016.09.010.
18. Stangier J, Stähle H, Rathgen K et al. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008; 47 (1): 47–59. doi: 10.2165/ 00003088-200 847010-00005.
37. Makunts T, Cohen IV, Awdishu L et al. Analysis of postmarketing safety data for proton-pump inhibitors reveals increased propensity for renal injury, electrolyte abnormalities and nephrolithiasis. Sci Rep 2019; 9 (1): 2282. 10.1038/ s41598-019-39335-7.
38. Makunts T, Alpatty S, Lee KC et al. Proton-pump inhibitor use is associated with a broad spectrum of neurological adverse events including impaired hearing, vision, and memory. Sci Rep 2019; 9 (1): 17280. doi: 10.1038/s41598-019-53622-3.
39. de la Coba Ortiz C, Arias FA, Mart C. Proton-pump inhibitors adverse efects: a review of the evidence and position statement by the Sociedad Espanola de Patologıa Digestiva. Rev Esp Enferm Dig 2016; 108 (4): 207–224. doi: 10.17235/reed.2016.4232/2016.
40. Joo MK, Park JJ, Chun HJ. Proton pump inhibitor: The dual role in gastric cancer. World J Gastroenterol 2019; 25 (17): 2058–2070. doi: 10.3748/wjg.v25.i17.2058.
41. Suissa S, Suissa A. Proton-pump inhibitors and increased gastric cancer risk: time-related biases. Gut 2018; 67 (12): 2228–2229. doi: 10.1136/gutjnl-2017-315729.
42. Abbas MK, Zaidi AZ, Robert CA et al. The safety of long-term daily usage of a proton pump inhibitor: A literature review 2019. Cureus 11 (9): e5563. doi: 10.7759/cureus.5563.
43. Poly TN, Islam MM, Yang HC et al. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies. Osteoporos Int 2019; 30 (1): 103–114. doi: 10.1007/s00198-018-4788-y.
44. Targownik LE, Lix LM, Metge CJ et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 2008; 179 (4): 319–326. doi: 10.1503/cmaj.071330.
45. Thong BK, Ima-Nirwana S, Chin KY. Proton pump inhibitors and fracture risk: A review of current evidence and mechanisms involved. Int J Environ Res Public Health 2019; 16 (9): 1571. doi: 10.3390/ijerph16091571.
46. Lee J, Youn K, Choi NK et al. A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate. J Gastroenterol 2013; 48 (9): 1016–1022. doi: 10.1007/s00535-012-0722-9.
47. Ruffenach SJ, Siskind MS, Lien YH: Acute interstitial nephritis due to omeprazole. Am J Med 1992; 93 (4): 472–473. doi: 10.1016/0002-9343 (92) 90181-a.
48. Blank ML, Parkin L, Paul C et al. A nationwide nested case control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use. Kidney Int 2014; 86 (4): 837–844. doi: 10.1038/ki.2014.74.
49. Antoniou T, Macdonald EM, Hollands S et al. Proton pump inhibitors and the risk of acute kidney injury in older patients: a population-based cohort study. CMAJ Open 2015; 3 (2): E166–E171. doi: 10.9778/cmajo.20140074.
50. Klepser DG, Collier DS, Cochran GL. Proton pump inhibitors and acute kidney injury: a nested case-control study. BMC Nephrol 2013; 16 (14): 150. doi: 10.1186/1471-2369-14-150.
51. Hart E, Dunn T E, Feuerstein S et al. Proton pump inhibitors and risk of acute and chronic kidney disease: a retrospective cohort study. Pharmacotherapy 2019; 39 (4): 443–453. doi: 10.1002/phar.2235.
52. De Francisco AL, Varas J, Ramos R et al. Proton pump inhibitor usage and the risk of mortality in hemodialysis patients. Kidney Int Rep 2017; 3 (2): 374–384. doi: 10.1016/j.ekir.2017.11.001.
53. Xie Y, Bowe B, Li T et al. Proton pump inhibitors and risk of incident CKD and progression to ESRD. J Am Soc Nephrol 2016; 27 (10): 3153–3163. doi: 10.1681/ASN.2015121377.
54. Lazarus B, Chen Y, Wilson FP et al: Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med 2016; 176 (2): 238–246. doi: 10.1001/jamainternmed.2015.7193.
55. Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W et al. Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies. Ren Fail 2015; 37 (7): 1237–1241. doi: 10.3109/0886022X.2015.1057800.
56. Toth-Manikowski SM, Grams ME. Proton pump inhibitors and kidney disease – GI upset for the nephrologist? Kidney Int Rep 2017; 2 (3): 297–301. doi: 10.1016/j.ekir.2017.01.005.
57. Keihani S, Craig JR, Zhang C et al. Proton-pump inhibitor use does not affect semen quality in subfertile men. Asian J Androl 2018, 20 (3): 290–293. doi: 10.4103/aja.aja_35_17.
58. Shaikh IA, Masood N, Shaikh TZ. Do proton pump inhibitors harm to semen? Hyderabad Sindh based study. Int J Sex Reprod Health Care 2019; 2 (1): 001–009.
59. Novotny M, Klimova B, Valis M. PPI long term use: risk of neurological adverse events? Front. Neurol 2019; 9: 1142. doi: 10.3389/fneur.2018.01142.
60. Khan MA, Yuan Y, Iqbal U et al. No association linking short-term proton pump inhibitor use to dementia: Systematic review and meta-analysis of observational studies. Am J Gastroenterol 2020; 115 (5): 671–678. doi: 10.14309/ajg.0000000000000500.
61. Wicinski M, Malinowski B, Puk O et al. Possible effects of proton pump inhibitors on hearing loss development. Biomed Res Int 2019; 4853695. doi: 10.1155/2019/4853695.
62. Lin BM, Curhan SG, Wang M et al. Prospective study of gastroesophageal reflux, use of proton pump inhibitors and H2-receptor antagonists, and risk of hearing loss. Ear Hear 2017; 38 (1): 21–27. doi: 10.1097/AUD.0000000000000347.
63. Tantai XX, Yang LB, Wei ZC et al. Association of proton pump inhibitors with risk of hepatic encephalopathy in advanced liver disease: A meta-analysis. World J Gastroenterol 2019; 25 (21): 2683–2698. doi: 10.3748/wjg.v25.i21.2683.
64. De Roza MA, Kai L, Kam JW et al. Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis. World J Gastroenterol 2019; 25 (33): 4933–4944. doi: 10.3748/wjg.v25.i33.4933.
65. Juurlink DN, Dormuth CR, Huang A et al. Proton pump inhibitors and the risk of adverse cardiac events. PLoS ONE 2013; 8 (12): e84890. doi: 10.1371/journal.pone.0084890.
66. Charlot M, Ahlehoff O, Norgard ML et al. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use. Ann Int Med 2010; 153 (6): 378–386.
67. Shih CJ, Chen YT, Ou SM et al. Proton pump inhibitor use represents an independent risk factor for myocardial infarction. Int J Cardiol 2014; 177 (1): 292–297.
68. Pello Lazaro AM, Cristobal C, Franco-Pelaez JA et al. Use of proton-pump inhibitors predicts heart failure and death in patients with coronary artery disease. PLoS ONE 2017; 12 (1): e0169826. doi: 10.1371/journal. pone.0169826.
69. Fortuna LA, Pawloski PA, Parker ED et al. Proton pump inhibitor use by aspirin-treated coronary artery disease patients is not associated with increased risk of cardiovascular events, Eur Heart J Cardiovasc Pharmacother 2016; 2 (1): 13–19. doi: 10.1093/ehjcvp/pvv036.
70. Shah NH, LePendu P, Bauer-Mehren A et al.Proton pump inhibitor usage and the risk of myocardial infarction in the general population, PLoS ONE 2015; 10 (6): e0124653. doi: 10.1371/journal.pone.0124653.
71. Landi SN, Sandler RS, Pate V et al. No increase in risk of acute myocardial infarction in privately insured adults prescribed proton pump inhibitors vs histamine-2 receptor antago­nists (2002–2014). Gastroenterology 2018; 154 (4): 861–873. doi: 10.1053/j.gastro.2017.10.042.
72. Xie Y, Bowe B, Yan Y et al. Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. BMJ 2019; 365: l1580. doi: 10.1136/bmj.l1580.
73. Lambert AA, Lam JO, Paik JJ et al. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: A systematic review and meta-analysis. PLoS ONE 2015; 10 (6): e0128004.doi: 10.1371/journal.pone.0128004.
74. Dublin S, Walker RL, Jackson ML et al. Use of proton pump inhibitors and H2 blockers and risk of pneumonia in older adults: a population-based case-control study. Pharmacoepidemiol Drug Saf 2010; 19 (8): 792–802. doi: 10.1002/pds.1978.
75. Wang YT, Tsai MC, Wang YH et al. Association between proton pump inhibitors and asthma: a population-based cohort study. Front. Pharmacol 2020; 11: 607. doi: 10.3389/fphar.2020.00607.
76. Lima JJ, Lang JE, Mougey EB et al. Association of CYP2C19 polymorphisms and lansoprazole-associated respiratory adverse effects in children. J Pediatr 2013; 163 (3): 686–691. doi: 10.1016/j.jpeds.2013.03.017.
77. Ivashkin V, Zolnikova O, Potskherashvili N et al.Metabolic activity of intestinal microflora in patients with bronchial asthma. Clin Pract 2019; 9 (11): 1126. doi: 10.4081/cp.2019.1126.
78. Robinson LB, Camargo CA Jr. Acid sup­pressant medications and the risk of allergic diseases. Expert Rev Clin Immunol 2018; 14 (9): 771–780. doi: 10.1080/1744666X.2018.1512405.
79. Devine RE, Sheikh A, Nwaru BI. Acid-suppressive medications during pregnancy and risk of asthma and allergy in the offspring: protocol for a systematic review. NPJ Prim Care Respir Med 2016; 26: 16001. doi: 10.1038/npjpcrm.2016.1.
80. Aggarwal N. Drug-induced subacute cutaneous lupus erythematosus associated with proton pump inhibitors. Drugs Real World Outcomes 2016; 3 (2): 145–154. doi: 10.1007/s40801-016-0067-4.
81. Brisebois S, Merati A, Giliberto JP. Proton pump inhibitors: Review of reported risks and controversies. Laryngoscope Investig Otolaryngol 2018; 3 (6): 457–462. doi: 10.1002/lio2.187.
82. Sibal L, Sharad C, Agarwal SC et al. The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease. Curr Cardiol Rev 2010; 6 (2): 82–90. doi: 10.2174/157340310791162659.

Kreditovaný autodidaktický test